Literature DB >> 17579661

ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.

M J Soler1, J Wysocki, M Ye, J Lloveras, Y Kanwar, D Batlle.   

Abstract

Angiotensin converting enzyme 2 (ACE2) is localized to the glomerular epithelial cells. Since ACE2 promotes the degradation of angiotensin II, a decrease in ACE2 activity could lead to the development of glomerular injury. We gave a specific ACE2 inhibitor, MLN-4760, for 4 weeks to mice rendered diabetic with streptozotocin. The urinary albumin/creatinine ratio was increased along with expansion of the glomerular matrix in diabetic mice treated with the inhibitor compared to the vehicle-treated mice. Glomerular staining of ACE was increased in the diabetic group and was further significantly increased in the diabetic group treated with MLN-4760. In renal vessels, ACE expression was also increased in the diabetic mice and, again, further increased in those diabetic mice treated with the ACE2 inhibitor. Our study shows that chronic pharmacologic ACE2 inhibition worsens glomerular injury in streptozotocin-induced diabetic mice in association with increased ACE expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579661     DOI: 10.1038/sj.ki.5002373

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  85 in total

Review 1.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

Review 2.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

Review 3.  The importance of the intrarenal renin-angiotensin system.

Authors:  Juan Carlos Q Velez
Journal:  Nat Clin Pract Nephrol       Date:  2008-12-09

4.  Of diabetic mice and ACE2: a new biomarker of renal disease?

Authors:  Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-17

5.  Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.

Authors:  Esam S B Salem; Nadja Grobe; Khalid M Elased
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-22

6.  ACE2 and diabetes: ACE of ACEs?

Authors:  Daniel Batlle; Maria Jose Soler; Minghao Ye
Journal:  Diabetes       Date:  2010-12       Impact factor: 9.461

Review 7.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 8.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

9.  Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.

Authors:  Elena Velkoska; Rachael G Dean; Luke Burchill; Vicki Levidiotis; Louise M Burrell
Journal:  Clin Sci (Lond)       Date:  2010-02       Impact factor: 6.124

10.  Human recombinant ACE2 reduces the progression of diabetic nephropathy.

Authors:  Gavin Y Oudit; George C Liu; Jiuchang Zhong; Ratnadeep Basu; Fung L Chow; Joyce Zhou; Hans Loibner; Evelyne Janzek; Manfred Schuster; Josef M Penninger; Andrew M Herzenberg; Zamaneh Kassiri; James W Scholey
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.